Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allion Healthcare names new CFO
Since 2003, Mr Fichera has served as CFO of EnduraCare Therapy Management. Prior to EnduraCare Therapy Management, Mr Fichera served as a financial executive in both publicly and
Since 2003, Mr Fichera has served as CFO of EnduraCare Therapy Management. Prior to EnduraCare Therapy Management, Mr Fichera served as a financial executive in both publicly and
The FDA has approved two additional configurations of Infuse Bone Graft – XX Small (0.7cc) kit and X Small (1.4cc) kit. These new sizes will be available for
The agreement covers Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and United Arab Emirates. Green Vision will be responsible for obtaining and maintaining product registrations in the
Each share of outstanding series D stock is entitled to receive a semi-annual cash dividend at an annual rate of 7%, to be cumulative until paid. As part
The single-center, Phase I trial examined the safety, tolerability and pharmacokinetics of escalating bolus doses of NU172 in normal, healthy volunteers. In the trial, NU172 produced dose-dependent increases
As part of this two-stage design, 15 patients with locally advanced or metastatic breast cancer have been enrolled initially. The primary objective of the multi-center, open-label study is
Since February of 2007, Mr Kochanski held the position of financial consultant director at Lordi Consulting. Prior to his tenure at Lordi, he spent three years with American
This trial is designed to evaluate both intravenous and oral formulations of CK-1827452 in patients with ischemic cardiomyopathy and angina. The primary objective of this trial is to
Based on the positive data from the trial, Cardica has submitted a 510(k) premarket notification to the FDA for the PAS-Port system. The PAS-Port system creates a secure
As a result of this supplemental new drug application (sNDA) approval, Sucampo will receive a development milestone payment of $50 million from Takeda in accordance with the collaboration